Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Executive Summary

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

Advertisement

Related Content

Theranexus's Novel Combo Disappoints In Narcolepsy
Lundbeck Looks For Assets Across Value Chain To Ride Storm
The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic
Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel